StockData

Abeona Therapeutics vs Viridian Therapeutics, Inc.\DE

ABEO and VRDN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABEO and VRDN compare

Viridian Therapeutics, Inc.\DE is the larger company, worth 23 times as much as Abeona Therapeutics ($3.4B against $149M).

Abeona Therapeutics keeps more of each dollar of sales as profit, with a net margin of −246% compared with −544% at Viridian Therapeutics, Inc.\DE.

Abeona Therapeutics scores higher on the StockData Score (8 against 4 for Viridian Therapeutics, Inc.\DE), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABEOVRDN
Size and price
Market cap$149M$3.4B
Share price$2.60$30.06
Change, 1 year−41.6%4.5%
Change, 5 years−85.8%64.3%
Beta (5Y)1.71−0.13
Employees226252
StockData Score
Total score8 (better)4
Valuation score3 (better)0
Growth score12 (better)
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/S5.8× (better)47.9×
P/B1.2× (better)5.1×
FCF yield−54.8%−9.8% (better)
Fair value$3.58$8.47
Margin of safety27.4% (better)−255%
Growth
Revenue growth (TTM)–23220%
Revenue growth, 5Y average−10.3%132% (better)
Net income growth (TTM)−210%–
Profitability
Gross margin67.1%–
Operating margin−328% (better)−570%
Net margin−246% (better)−544%
FCF margin−319% (better)−471%
Return on equity−43.1% (better)−65.7%
Financial health
Debt / equity0.12–
Interest coverage−25.3× (better)−26.0×
Current ratio6.6316.95 (better)
Altman Z-score−4.802.65 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield–−1.7%
Shareholder yield0.00% (better)−1.7%
Ownership
Held by institutions77.9%120%
Held by insiders12.3%21.8%
Insider net buying, 12 months−$3.5M$19.6M (better)
Short interest, % of float33.7%19.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.